Results 101 to 110 of about 78,982 (256)

Granulomatous Lymphangitis Masquerading as Relapsed Hodgkin Disease on FDG PET/CT. [PDF]

Tomography, 2018
Mustafa M, Patel D, Shen L, Shetty A, Mansberg R.   +4 more
europepmc   +1 more source

Diagnostic Yield of EBUS Mediastinal Cryobiopsy Versus TBNA in Suspected Lymphoproliferative Disorders: A Prospective Multicentre Study

Respirology, EarlyView.
We assessed the diagnostic yield of EBUS‐guided transbronchial mediastinal cryobiopsy (EBUS‐TBMC) compared with EBUS‐transbronchial needle aspiration (EBUS‐TBNA) in patients with suspected mediastinal lymphoproliferative disorders (LPDs). EBUS‐TBMC was superior to EBUS‐TBNA and achieved a high diagnostic yield in patients with suspected mediastinal ...
Yaniv Dotan, Ayal Romem, Elad Guber, Michael Kassirer, Daphne Felus, Nimrod Urtreger, Ophir Freund, Hanna A. Dawood, Boaz Tiran, Doron Cohn‐Schwartz, Sarah Borsekofsky, Amir Bar‐Shai, Evgeni Gershman   +12 more
wiley   +1 more source

Idiopathic Thrombocytopenia Purpura Masking Hodgkin Disease: A Paraneoplastic Syndrome or Simply a Mere Association? [PDF]

Case Rep Oncol, 2017
Poponea N, Suede M, Muhsin Chisti M.
europepmc   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Building a precision therapeutics program at a tertiary care children's hospital

Pediatric Investigation, EarlyView.
Luke Hamilton, Heidi Trinkman, Diana Carrasco, Kaitlin Smith, Kelly Vallance, Alejandra Dominguez, Danielle Miller, Megan Gibbs, Anish Ray   +8 more
wiley   +1 more source

Nanomedicine applications in lymphoma: Advancing precision diagnostics, targeted therapeutics, and prospective developments

VIEW, EarlyView.
Lymphoma is a group of blood cancers that can appear in lymph nodes, blood, bone marrow, spleen, liver, or the central nervous system, which makes drug delivery and disease monitoring difficult. This review summarizes how nanomedicine technologies may improve targeted treatment and imaging, while carefully separating approved or guideline‐supported ...
Mohd Ahmar Rauf, Yara Mashal, Afeefa Rao, Nasar Ata, Arun K. Iyer, Farhan Shah   +5 more
wiley   +1 more source

Review on enhancing clinical decision support system using machine learning

CAAI Transactions on Intelligence Technology, EarlyView.
Abstract Clinical decision‐making is a complex patient‐centred process. For an informed clinical decision, the input data is very thorough ranging from detailed family history, environmental history, social history, health‐risk assessments, and prior relevant medical cases.
Anum Masood, Usman Naseem, Junaid Rashid, Jungeun Kim, Imran Razzak   +4 more
wiley   +1 more source

Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5‐Year Analysis of the Phase 3 POETYK PSO‐1, PSO‐4, and Long‐Term Extension Trials

The Journal of Dermatology, EarlyView.
ABSTRACT Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, is approved in multiple countries for the treatment of moderate to severe plaque psoriasis, as well as generalized pustular and erythrodermic psoriasis in Japan. Deucravacitinib 6 mg once daily was efficacious and well tolerated through 3 years in the pooled population of ...
Yukari Okubo, Akimichi Morita, Yayoi Tada, Shinichi Imafuku, April W. Armstrong, Andrew Blauvelt, John Vaile, Zoran Popmihajlov, Janice Li, Rajesh Sawant, Katsuyoshi Habiro, Katsuki Tsuritani, Mamitaro Ohtsuki   +12 more
wiley   +1 more source